BRPI0706487A2 - métodos de tratamento de inflamação em tecido neuronal de um mamìfero, de tratamento de dor em um mamìfero, de antagonizar transdução de sinal induzida por il-31 em células de gánglio da raiz dorsal, de tratamento de sintomas associados com queimadura, de tratamento de sintomas associados com infecção viral em um mamìfero, e, de tratamento de dor associada com doença intestinal inflamatória - Google Patents

métodos de tratamento de inflamação em tecido neuronal de um mamìfero, de tratamento de dor em um mamìfero, de antagonizar transdução de sinal induzida por il-31 em células de gánglio da raiz dorsal, de tratamento de sintomas associados com queimadura, de tratamento de sintomas associados com infecção viral em um mamìfero, e, de tratamento de dor associada com doença intestinal inflamatória Download PDF

Info

Publication number
BRPI0706487A2
BRPI0706487A2 BRPI0706487-0A BRPI0706487A BRPI0706487A2 BR PI0706487 A2 BRPI0706487 A2 BR PI0706487A2 BR PI0706487 A BRPI0706487 A BR PI0706487A BR PI0706487 A2 BRPI0706487 A2 BR PI0706487A2
Authority
BR
Brazil
Prior art keywords
thr
glu
lys
val
leu
Prior art date
Application number
BRPI0706487-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Yue Yao
Janine Bilsborough
Cecile Krejsa
Linda Zuckerman
Mark Rogge
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of BRPI0706487A2 publication Critical patent/BRPI0706487A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0706487-0A 2006-01-10 2007-01-10 métodos de tratamento de inflamação em tecido neuronal de um mamìfero, de tratamento de dor em um mamìfero, de antagonizar transdução de sinal induzida por il-31 em células de gánglio da raiz dorsal, de tratamento de sintomas associados com queimadura, de tratamento de sintomas associados com infecção viral em um mamìfero, e, de tratamento de dor associada com doença intestinal inflamatória BRPI0706487A2 (pt)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US75806606P 2006-01-10 2006-01-10
US75797906P 2006-01-10 2006-01-10
US60/757,979 2006-01-10
US60/758,066 2006-01-10
US77303106P 2006-02-14 2006-02-14
US60/773,031 2006-02-14
US80555006P 2006-06-22 2006-06-22
US80555206P 2006-06-22 2006-06-22
US80555406P 2006-06-22 2006-06-22
US60/805,550 2006-06-22
US60/805,552 2006-06-22
US60/805,554 2006-06-22
US82398706P 2006-08-30 2006-08-30
US82398206P 2006-08-30 2006-08-30
US60/823,982 2006-08-30
US60/823,987 2006-08-30
PCT/US2007/060330 WO2007143231A2 (en) 2006-01-10 2007-01-10 Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists

Publications (1)

Publication Number Publication Date
BRPI0706487A2 true BRPI0706487A2 (pt) 2011-03-29

Family

ID=38694567

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0706487-0A BRPI0706487A2 (pt) 2006-01-10 2007-01-10 métodos de tratamento de inflamação em tecido neuronal de um mamìfero, de tratamento de dor em um mamìfero, de antagonizar transdução de sinal induzida por il-31 em células de gánglio da raiz dorsal, de tratamento de sintomas associados com queimadura, de tratamento de sintomas associados com infecção viral em um mamìfero, e, de tratamento de dor associada com doença intestinal inflamatória

Country Status (11)

Country Link
US (22) US7514077B2 (enExample)
EP (4) EP2001906A2 (enExample)
JP (3) JP2009528264A (enExample)
KR (1) KR101345586B1 (enExample)
AU (2) AU2007249713A1 (enExample)
BR (1) BRPI0706487A2 (enExample)
CA (2) CA2633439A1 (enExample)
IL (4) IL192130A0 (enExample)
MX (1) MX2008008831A (enExample)
RU (1) RU2565391C2 (enExample)
WO (2) WO2007133816A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
EP1221482B1 (en) 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Hemopoietin receptor protein, nr12
RU2490276C2 (ru) 2002-01-18 2013-08-20 Займоджинетикс, Инк. Новый лиганд рецептора цитокина zcytor17
EP1858924A1 (en) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP4927762B2 (ja) 2005-02-14 2012-05-09 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
CN101198624B (zh) * 2005-05-06 2012-10-10 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
EP2001906A2 (en) 2006-01-10 2008-12-17 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
EP4793360A2 (en) * 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
ES2544888T3 (es) * 2006-06-08 2015-09-04 Chugai Seiyaku Kabushiki Kaisha Prevención o remedio para enfermedades inflamatorias
EP2061811A2 (en) 2006-09-01 2009-05-27 ZymoGenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
AU2008204823A1 (en) 2007-01-10 2008-07-17 Zymogenetics, Inc Methods of using IL-31 to treat airway hyper-responsiveness and asthma
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
CA2708065C (en) * 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
SI2796466T1 (en) 2007-12-07 2018-01-31 Zymogenetics, Inc. Molecules of Humanized Specifics Specifiable for IL-31
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
EP2348128A1 (en) * 2010-01-21 2011-07-27 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US10039792B1 (en) 2013-03-16 2018-08-07 Brahm Holdings, Llc Methods for the treatment of inflammation and pain using human birth tissue material composition
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
HUE056580T2 (hu) 2013-05-30 2022-02-28 Kiniksa Pharmaceuticals Ltd Onkosztatin-M-receptor antigénjét kötõ fehérjék
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
EP3250599B1 (en) * 2015-01-29 2021-04-14 Oxford University Innovation Limited Biomarker
FI3284480T3 (fi) 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
WO2017033951A1 (ja) * 2015-08-24 2017-03-02 学校法人国際医療福祉大学 新規鎮痛剤
JP6728352B2 (ja) * 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
US11319372B2 (en) 2017-02-21 2022-05-03 Remd Biotherapeutics, Inc. Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)
EP3586187B1 (en) 2017-02-23 2024-01-03 Magic Leap, Inc. Display system with variable power reflector
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
JP7067800B2 (ja) * 2017-04-12 2022-05-16 国立大学法人九州大学 神経障害性疼痛マーカー及びその使用
CA3093709C (en) 2018-03-16 2024-03-26 Zoetis Services Llc Peptide vaccines against interleukin-31
JP7449234B2 (ja) 2018-03-16 2024-03-13 ゾエティス・サービシーズ・エルエルシー 獣医学使用のためのインターロイキン３１モノクローナル抗体
CN118512451A (zh) 2018-07-23 2024-08-20 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
RU2707954C1 (ru) * 2019-01-24 2019-12-02 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения онкологической боли
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
WO2021100794A1 (ja) 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
CA3189847A1 (en) * 2020-09-01 2022-03-10 Naoki Fukazawa Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
WO2025226834A1 (en) * 2024-04-23 2025-10-30 Attovia Therapeutics, Inc. Il31-binding polypeptides and uses thereof
WO2026055142A1 (en) 2024-09-03 2026-03-12 Attovia Therapeutics, Inc. Il13 and il31 bispecific polypeptides and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US750795A (en) * 1904-02-02 Eugene j
US4054646A (en) 1973-07-30 1977-10-18 General Electric Method and apparatus for detection of antibodies and antigens
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5492841A (en) 1994-02-18 1996-02-20 E. I. Du Pont De Nemours And Company Quaternary ammonium immunogenic conjugates and immunoassay reagents
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US5792850A (en) * 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
WO2002008288A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
RU2175874C2 (ru) * 1999-03-17 2001-11-20 Борисов Виктор Александрович Способ лечения нарушений функций центральной нервной системы и устройство для его осуществления
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2075253A1 (en) 2000-06-23 2009-07-01 Genentech, Inc. Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
EP1325115B1 (en) 2000-06-26 2016-07-27 ZymoGenetics, Inc. Cytokine receptor zcytor17
US20030059871A1 (en) 2000-10-06 2003-03-27 Cosman David J. Hematopoietin receptors HPR1 and HPR2
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
RU2490276C2 (ru) * 2002-01-18 2013-08-20 Займоджинетикс, Инк. Новый лиганд рецептора цитокина zcytor17
WO2004003140A2 (en) 2002-01-18 2004-01-08 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
US7303896B2 (en) 2002-02-25 2007-12-04 Genentech, Inc. Nucleic acid encoding novel type-1 cytokine receptor GLM-R
ES2579758T3 (es) 2005-01-28 2016-08-16 Zymogenetics, Inc. Preparaciones homogéneas de IL-31
EP1858924A1 (en) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP4927762B2 (ja) 2005-02-14 2012-05-09 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
CN101198624B (zh) 2005-05-06 2012-10-10 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
EP2001906A2 (en) 2006-01-10 2008-12-17 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
EP2061811A2 (en) 2006-09-01 2009-05-27 ZymoGenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
AU2008204823A1 (en) 2007-01-10 2008-07-17 Zymogenetics, Inc Methods of using IL-31 to treat airway hyper-responsiveness and asthma
SI2796466T1 (en) 2007-12-07 2018-01-31 Zymogenetics, Inc. Molecules of Humanized Specifics Specifiable for IL-31

Also Published As

Publication number Publication date
US8685395B2 (en) 2014-04-01
JP2013047259A (ja) 2013-03-07
US9631022B2 (en) 2017-04-25
AU2007249713A1 (en) 2007-11-22
US8377438B2 (en) 2013-02-19
US20130177562A1 (en) 2013-07-11
US20180066050A1 (en) 2018-03-08
US20170190780A1 (en) 2017-07-06
US7514077B2 (en) 2009-04-07
US8968732B2 (en) 2015-03-03
EP2749571A2 (en) 2014-07-02
US20190119372A1 (en) 2019-04-25
IL192296A0 (en) 2009-08-03
KR101345586B1 (ko) 2013-12-31
US20170190771A1 (en) 2017-07-06
IL219678A0 (en) 2012-06-28
RU2565391C2 (ru) 2015-10-20
IL219677A0 (en) 2012-06-28
US8974783B2 (en) 2015-03-10
US9334321B2 (en) 2016-05-10
WO2007133816A2 (en) 2007-11-22
KR20080108413A (ko) 2008-12-15
US20120107310A1 (en) 2012-05-03
US20140186346A1 (en) 2014-07-03
US8105591B2 (en) 2012-01-31
US20150132300A1 (en) 2015-05-14
WO2007143231A3 (en) 2009-08-27
US9334322B2 (en) 2016-05-10
WO2007133816A3 (en) 2010-11-18
US20070160610A1 (en) 2007-07-12
RU2011137369A (ru) 2013-03-20
US9631021B2 (en) 2017-04-25
WO2007143231A2 (en) 2007-12-13
JP2009526756A (ja) 2009-07-23
CA2633439A1 (en) 2007-11-22
EP1991581A2 (en) 2008-11-19
US20160222123A1 (en) 2016-08-04
US20100297125A1 (en) 2010-11-25
US20190112369A1 (en) 2019-04-18
US20130195855A1 (en) 2013-08-01
US20070160611A1 (en) 2007-07-12
EP2594585A1 (en) 2013-05-22
US9828431B2 (en) 2017-11-28
EP2001906A2 (en) 2008-12-17
US7638126B2 (en) 2009-12-29
US20180044426A1 (en) 2018-02-15
JP2009528264A (ja) 2009-08-06
US20160222103A1 (en) 2016-08-04
US20110177072A1 (en) 2011-07-21
US8105590B2 (en) 2012-01-31
CA2636288A1 (en) 2007-12-13
US20120207757A1 (en) 2012-08-16
EP2749571A3 (en) 2014-08-13
US20150132299A1 (en) 2015-05-14
US8637015B2 (en) 2014-01-28
US7939068B2 (en) 2011-05-10
AU2007254715B2 (en) 2013-08-29
US9834602B2 (en) 2017-12-05
MX2008008831A (es) 2009-03-04
US7943132B2 (en) 2011-05-17
US8409571B2 (en) 2013-04-02
US20140127206A1 (en) 2014-05-08
IL192130A0 (en) 2009-08-03
AU2007254715A1 (en) 2007-12-13
CA2636288C (en) 2015-02-24
US20100221244A1 (en) 2010-09-02
US20110177086A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
US9828431B2 (en) Use of IL-31RA monoclonal antibodies for treating neuronal inflammation
AU2013204175A1 (en) Methods of Treating Pain and Inflammation in Neuronal Tissue Using IL-31 Antagonists

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL